… that the subgroup effects on the DAPA-HF primary endpoint represented the treatment …
DAPA-HF and EMPEROR-Reduced also differed slightly, we used the definition of the DAPA-HF …

… The principal difference between the two trials was that patients with an ejection fraction
≤40% were randomized in DAPA-HF and those with an ejection fraction >40% in DELIVER. In …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated with …

… in DAPA-HF were obtained … DAPA-HF was in keeping with other reports in large cohorts of
patients with HFrEF, predominantly in New York Heart Association class II and III. In DAPA-HF, …

… of health status using KCCQ in the DAPA-HF trial, we observed that treatment with … composite
end point of cardiovascular death or worsening HF, and its components, to a similar extent …

… Left ventricular ejection fraction was slightly higher in DAPA-HF than in the other two
trials whereas NT-proBNP levels were broadly similar in all three trials. Heart rate and blood …

… mortality and HF hospitalization and improved symptoms in 4744 patients with HF and
reduced ejection fraction (HFrEF). The average age of patients randomized in DAPA-HF was 66 …

Aims The aim of this study was to examine whether left ventricular ejection fraction (LVEF)
modified efficacy and safety of dapagliflozin 10 mg compared with placebo in the 4744 …

… a first episode of worsening heart failure (HF) in patients with heart failure and reduced
ejection fraction (HFrEF). In this analysis of DAPA-HF, we describe the efficacy of dapagliflozin on …

… Our findings in DAPA-HF were qualitatively similar to those in PARADIGM-HF with the most
… pg/mL 9 and, although most patients in DAPA-HF had a baseline concentration >400 pg/mL, …